Hong Kong Basic Materials Stock News

China Everbright (SEHK:165) has been dropped from the FTSE All-World Index (USD). This type of change often prompts mechanical selling as index-tracking funds and benchmarked investors adjust positions. Recent trading has been choppy for China Everbright. The share price has climbed over the short term, with a 10.14% 30 day share price return and 14.50% over 90 days. However, the year to date share price return is down 33.11% and the 1 year total shareholder return has fallen 28.66%, while...

Orient Overseas (International) (SEHK:316) has drawn fresh attention after recent trading left the share price at HK$146.30. These short term moves contrast sharply with the performance over the past 3 years. For context, Orient Overseas (International) has seen a sharp 30-day share price return of down 17.2%, even though the 90-day share price return is up 19.7%. Meanwhile, the 3-year total shareholder return of 73.9% and 5-year total shareholder return of 127.8% show a much stronger longer...

Chinese biopharma developers just caught a rare break. Fresh signals from Washington suggest U.S. pharma groups may keep licensing most drugs from Chinese partners, and the Hang Seng Biotech Index has already reacted. This keeps the door open for cross-border deals that can reshape how companies fund pipelines and share risk. This article walks through three Chinese biopharma stocks exposed to this news and why that matters for your portfolio decisions. The stocks covered below are just a...

On 17 September 2026, XtalPi Holdings announced that subsidiary LCC Technologies entered a drug discovery collaboration with Stanford University, pairing Stanford’s disease biology research with LCC’s AI-driven PACE platform for small molecule development across multiple disease areas. The agreement creates a joint steering committee that screens Stanford investigators’ proposals and directs LCC’s automated discovery resources toward the projects with the strongest scientific rationale and...

Ascletis Pharma (SEHK:1672) has kicked off a U.S. Phase I trial for ASC36 oral tablets for obesity treatment, following recent FDA Investigational New Drug clearance that advances the obesity pipeline into human testing. Ascletis Pharma’s latest obesity trial news hit as the HK$8.97 share price jumped with a 1-day share price return of 10.13%. However, the 30-day share price return is down 10.48% and the year-to-date share price return is down 22.14%, while the 3-year total shareholder return...

China Resources Land (SEHK:1109) just released unaudited sales figures for August 2026, providing fresh data on contracted sales momentum and recurring income trends across its mainland China property portfolio. For context, China Resources Land’s share price is HK$28.64, and the stock has slipped 19.05% on a 30 day share price return and 8.15% over 90 days, even though the year to date share price return is up 3.32% and the 5 year total shareholder return of 21.69% suggests longer term...

China Modern Dairy Holdings (SEHK:1117) has drawn fresh attention after recent share price moves, with the stock closing at HK$1.645 and showing mixed short term returns alongside strong multi year total return figures. The recent move to HK$1.645 follows a strong 90 day share price return of 66.16% and a 1 year total shareholder return of 29.53%. This suggests momentum around China Modern Dairy Holdings has been building as investors reassess both growth prospects and risks. Compare how...

SJM Holdings Limited was removed from the FTSE All-World Index (USD) on 19 September 2026, a shift that can influence how global index trackers and benchmarked investors view the stock within diversified portfolios. This exit from a major global benchmark may prompt some passive funds to sell SJM Holdings, which can affect liquidity, ownership mix, and market perception of the business fundamentals behind its casino and hospitality operations. Attention now turns to how SJM Holdings' removal...

The Asian markets have been navigating a complex landscape marked by fluctuating oil prices and evolving monetary policies, with investors keenly watching for signs of stability amid regional economic shifts. In this environment, identifying undervalued stocks can offer strategic opportunities for investors seeking to capitalize on potential growth in the region.

As September 2026 unfolds, the Asian markets are navigating a complex landscape marked by fluctuating oil prices and central bank rate hikes, with Japan's stock indices experiencing gains amid easing concerns over Middle East supply disruptions. In this environment of volatility and opportunity, identifying promising stocks requires a focus on companies that demonstrate resilience and adaptability in the face of economic shifts.

United Laboratories International Holdings reported that its subsidiary has dosed the first participant in two Phase III UBT251 studies in China, testing a long-acting GLP-1/GIP/GCG triple agonist for adults with type 2 diabetes across placebo and semaglutide controlled designs. The drug is already cleared for clinical trials in China and the United States across several metabolic indications and has been out-licensed to Novo Nordisk, which reinforces the commercial relevance of UBT251 in...

Air China reported August 2026 operating data, including 36,577.6 million available seat kilometers, 32,064.0 million revenue passenger kilometers, an 87.7% passenger load factor, and 16,683,300 passengers flown, alongside detailed cargo and overall load metrics. The carrier’s year to date figures show 252,904.7 million available seat kilometers and 215,478.2 million revenue passenger kilometers, with an 85.2% passenger load factor that gives investors a view of how Air China is filling its...

Wharf Real Estate Investment (SEHK:1997) has put cash returns front and center after announcing a first interim dividend of HK$0.94 per share, up from HK$0.66 a year earlier. That cash signal comes after a sharp 90 day share price return of 42.96% and a year to date gain of 20.76% at a latest share price of HK$30.48. The 1 year total shareholder return of 36.81% points to momentum that has been building rather than fading. Scan for other income focused real estate plays showing strong cash...

Weichai Power (SEHK:2338) has put two investor focused decisions on the table: a new cash dividend for H shares and a supplemental sales agreement with Shaanxi Automotive. Together, these moves reshape both cash flows and commercial ties. Weichai Power’s share price has pulled back over the past month, with a 30 day share price return of a 5.15% decline and a 90 day share price return of a 22.68% decline. However, the year to date share price return of 67.02% and a 1 year total shareholder...

Meitu (SEHK:1357) has pushed its AI ambitions further with MVLAND Version 2.0, introducing a new Studio Mode that integrates music analysis, storytelling tools, and detailed shot-level video controls for creators. The MVLAND upgrade comes at a tricky moment for Meitu shareholders. The stock closed at HK$4.035 after a 1-day share price gain of 5.77%. However, the 30-day share price return is down 8.92% and the year-to-date share price return has fallen 45.69%, while the 5-year total...

Some Maiyue Technology Limited ( HKG:2501 ) shareholders may be a little concerned to see that the Co-CEO & Executive...

Readers hoping to buy Lee's Pharmaceutical Holdings Limited ( HKG:950 ) for its dividend will need to make their move...

Longfor Group Holdings reported unaudited August 2026 figures, with contracted sales of RMB 2.20b on 250,000 sqm and year-to-date contracted sales of RMB 20.84b on 2,239,000 sqm, alongside RMB 18.18b of aggregated revenue excluding tax from property operation and property service. The split between approximately RMB 9.73b of operating income and RMB 8.45b of service income reflects how Longfor Group Holdings relies on both property sales and recurring services as key pillars of its business...

Shanghai Henlius Biotech (SEHK:2696) drew attention after regulators in mainland China accepted its New Drug Application for HLX14, a denosumab biosimilar targeting cancer related bone disease and giant cell tumor of bone. The regulatory progress comes as Shanghai Henlius Biotech’s 1-day share price return of 2.23% contrasts with a 7-day decline of 5.24% and a 30-day drop of 12.97%. The year-to-date share price return of 1.88% sits beside a 1-year total shareholder return that declined 23.07%...

Investors who take an interest in PATEO CONNECT Technology (Shanghai) Corporation ( HKG:2889 ) should definitely note...

China Reinsurance (Group) held a board meeting on 6 September 2026 to review a general mandate for new share issuance, a domestic share placement to a specific investor, related authorisations, and a conditional share subscription agreement. The focus on authorising fresh equity and a targeted domestic investor highlights how China Reinsurance (Group) may adjust its capital mix and shareholder base to support operating priorities in reinsurance, climate risk cover, and EV-related...

Amidst a backdrop of mixed performance across global markets, Asian equities have shown resilience with notable activity in technology and energy sectors. While the term "penny stock" might evoke images of speculative ventures from yesteryears, it still captures the essence of smaller or emerging companies that can offer substantial value when underpinned by strong financials. By focusing on balance sheet strength and growth potential, investors can uncover promising opportunities in these...

China Resources Power Holdings: Renewable output picks up pace China Resources Power Holdings (SEHK:836) has released new figures, with August and year-to-date operating data indicating higher total power generation and faster growth from its wind and solar subsidiaries. China Resources Power Holdings shares trade at HK$18.89 and the stock has built a steady positive trend, with a 30-day share price return of 5.53% and a 1-year total shareholder return of 10.41%. The 3-year total shareholder...

Shenzhen HQVT Technology (SEHK:1392) has drawn attention after a sharp move in the share price over the past week. This invites a closer look at how its AI-focused business profile lines up with recent trading. Recent trading has been intense. Shenzhen HQVT Technology's share price return over the past week sits at 95.59%, on top of a 30 day share price return of 78.43% and a year to date share price return of 39.40%. This points to rapidly building momentum rather than a slow grind...